Immunization with Amyloid-β Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse Model
暂无分享,去创建一个
[1] C. Masters,et al. Intracellular amyloid formation in muscle cells of Aβ-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification , 2009, Molecular Neurodegeneration.
[2] W. Engel,et al. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains , 2008, Acta Neuropathologica.
[3] T. Wisniewski,et al. Amyloid-β immunisation for Alzheimer's disease , 2008, The Lancet Neurology.
[4] F. LaFerla,et al. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase‐3β , 2008, Annals of neurology.
[5] M. Dalakas,et al. Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle , 2008, Brain : a journal of neurology.
[6] F. Mastaglia,et al. Sporadic inclusion body myositis: a continuing puzzle , 2008, Neuromuscular Disorders.
[7] Sara E. Miller,et al. Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. , 2007, Human molecular genetics.
[8] I. Nonaka,et al. A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. , 2007, Human molecular genetics.
[9] F. LaFerla,et al. Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles* , 2006, Journal of Biological Chemistry.
[10] W. Engel,et al. AβPP-overexpression and proteasome inhibition increase αB-crystallin in cultured human muscle: Relevance to inclusion-body myositis , 2006, Neuromuscular Disorders.
[11] M. Dalakas,et al. Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies , 2006, Nature Clinical Practice Neurology.
[12] B. Kriem,et al. Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway , 2006, Neurobiology of Disease.
[13] Anna Fidziańska,et al. Rimmed vacuoles with beta-amyloid and tau protein deposits in the muscle of children with hereditary myopathy , 2006, Acta Neuropathologica.
[14] H. Weiner,et al. Aβ-induced meningoencephalitis is IFN-γ-dependent and is associated with T cell-dependent clearance of Aβ in a mouse model of Alzheimer's disease , 2006 .
[15] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[16] Marinos C. Dalakas,et al. Inflammatory, immune, and viral aspects of inclusion-body myositis , 2006, Neurology.
[17] W. Klein,et al. Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.
[18] H. Weiner,et al. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. , 2005, The Journal of clinical investigation.
[19] W. Engel,et al. Molecular pathology and pathogenesis of inclusion‐body myositis , 2005, Microscopy research and technique.
[20] Makoto Hashimoto,et al. Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.
[21] Ian Parker,et al. Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*♦ , 2005, Journal of Biological Chemistry.
[22] J. D. McGaugh,et al. Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.
[23] Randomized pilot trial of high-dose βINF-1a in patients with inclusion body myositis , 2004, Neurology.
[24] David H. Cribbs,et al. Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.
[25] Isidro Ferrer,et al. Proteasomal Expression, Induction of Immunoproteasome Subunits, and Local MHC Class I Presentation in Myofibrillar Myopathy and Inclusion Body Myositis , 2004, Journal of neuropathology and experimental neurology.
[26] A. Pestronk,et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.
[27] P. Lansbury,et al. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. , 2003, Annual review of neuroscience.
[28] C. Finch,et al. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[29] V. Askanas,et al. Cystatin C colocalizes with amyloid‐β and coimmunoprecipitates with amyloid‐β precursor protein in sporadic inclusion‐body myositis muscles , 2003 .
[30] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[31] C. Cotman,et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. , 2003, International immunology.
[32] J. Crabbe,et al. Assessment of genetic susceptibility to ethanol intoxication in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] Julio C. Echegoyen,et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of βAPP in skeletal muscle , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[34] K J Felice,et al. A pilot randomized trial of oxandrolone in inclusion body myositis , 2002, Neurology.
[35] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[36] G. Tate,et al. Hereditary motor and sensory neuropathy with minifascicle formation in a patient with 46XY pure gonadal dysgenesis: A new clinical entity , 2002, Annals of neurology.
[37] N. Niikawa,et al. Nonaka myopathy is caused by mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase gene (GNE) , 2002, Journal of Human Genetics.
[38] Tsviya Olender,et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy , 2001, Nature Genetics.
[39] Michael J. Rowan,et al. Amyloid-β oligomers: their production, toxicity and therapeutic inhibition , 2001 .
[40] David J. Cummins,et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] Kenneth M. Rosen,et al. β-Amyloid Peptide Expression Is Sufficient for Myotube Death: Implications for Human Inclusion Body Myopathy , 2001, Molecular and Cellular Neuroscience.
[42] S. Spector,et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM , 2001, Neurology.
[43] N. Darín,et al. Autosomal dominant myopathy: missense mutation (Glu-706 --> Lys) in the myosin heavy chain IIa gene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[44] Kristi Kincaid,et al. M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.
[45] J. Crabbe,et al. Sensitivity to Ethanol-Induced Motor Incoordination in FAST and SLOW Selectively Bred Mice , 2000, Pharmacology Biochemistry and Behavior.
[46] Andrew G. Engel,et al. αB-Crystallin immunolocalization yields new insights into inclusion body myositis , 2000, Neurology.
[47] J R Lindsey,et al. Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. , 1998, The American journal of pathology.
[48] George M. Martin,et al. Transgenic Mice Over-Expressing the C-99 Fragment of βPP with an α-Secretase Site Mutation Develop a Myopathy Similar to Human Inclusion Body Myositis , 1998 .
[49] W. Engel,et al. Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: relevance to inclusion‐body myopathies , 1998, Neuroreport.
[50] B. Heyman,et al. Impaired antibody responses in H-2Ab mice. , 1998, Journal of immunology.
[51] Xudong Huang,et al. Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis* , 1998, The Journal of Biological Chemistry.
[52] W. Engel,et al. β‐Amyloid precursor epitopes in muscle fibers of inclusion body myositis , 1993 .
[53] K. Beyreuther,et al. Amyloidogenicity of rodent and human βA4 sequences , 1993 .
[54] W. Engel,et al. beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. , 1993, Neuroreport.
[55] D. Selkoe,et al. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. , 1992, Biochemistry.
[56] W. Engel,et al. Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy , 1991, Neuroscience Letters.
[57] H. Weiner,et al. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[58] F. LaFerla,et al. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. , 2006, The American journal of pathology.
[59] Michela Gallagher,et al. A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.
[60] W. Klein,et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. , 2006, The Journal of biological chemistry.
[61] E. Masliah,et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.
[62] W. Engel,et al. Cystatin C colocalizes with amyloid-beta and coimmunoprecipitates with amyloid-beta precursor protein in sporadic inclusion-body myositis muscles. , 2003, Journal of neurochemistry.
[63] M. Rowan,et al. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. , 2002, Biochemical Society transactions.
[64] D. Holtzman,et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[65] M. Toepfer,et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study , 2000, Journal of Neurology.
[66] B. Banwell,et al. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. , 2000, Neurology.
[67] G. Martin,et al. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. , 1998, The American journal of pathology.
[68] R. Locksley,et al. The regulation of immunity to Leishmania major. , 1995, Annual review of immunology.
[69] D. Selkoe,et al. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. , 1994, The American journal of pathology.
[70] K. Beyreuther,et al. Amyloidogenicity of rodent and human beta A4 sequences. , 1993, FEBS letters.
[71] H. Mantsch,et al. Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. , 1993, European journal of biochemistry.
[72] W. Engel,et al. beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. , 1993, Annals of neurology.
[73] Transgenic expression of (cid:1) -APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology , 2022 .